Logo image of PHAT

PHATHOM PHARMACEUTICALS INC (PHAT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PHAT - US71722W1071 - Common Stock

14.93 USD
+0.11 (+0.74%)
Last: 11/25/2025, 8:06:46 PM
14.64 USD
-0.29 (-1.94%)
After Hours: 11/25/2025, 8:06:46 PM
Fundamental Rating

2

PHAT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. PHAT may be in some trouble as it scores bad on both profitability and health. PHAT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PHAT had negative earnings in the past year.
In the past year PHAT has reported a negative cash flow from operations.
In the past 5 years PHAT always reported negative net income.
In the past 5 years PHAT always reported negative operating cash flow.
PHAT Yearly Net Income VS EBIT VS OCF VS FCFPHAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

The Return On Assets of PHAT (-114.26%) is worse than 79.17% of its industry peers.
Industry RankSector Rank
ROA -114.26%
ROE N/A
ROIC N/A
ROA(3y)-85.69%
ROA(5y)-75.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PHAT Yearly ROA, ROE, ROICPHAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

PHAT has a Gross Margin of 87.25%. This is amongst the best in the industry. PHAT outperforms 89.58% of its industry peers.
The Profit Margin and Operating Margin are not available for PHAT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PHAT Yearly Profit, Operating, Gross MarginsPHAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K -25K

More info and screens

2

2. Health

2.1 Basic Checks

PHAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PHAT has been increased compared to 1 year ago.
The number of shares outstanding for PHAT has been increased compared to 5 years ago.
PHAT has a worse debt/assets ratio than last year.
PHAT Yearly Shares OutstandingPHAT Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
PHAT Yearly Total Debt VS Total AssetsPHAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

PHAT has an Altman-Z score of -9.31. This is a bad value and indicates that PHAT is not financially healthy and even has some risk of bankruptcy.
PHAT has a Altman-Z score of -9.31. This is in the lower half of the industry: PHAT underperforms 68.23% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.31
ROIC/WACCN/A
WACC8.13%
PHAT Yearly LT Debt VS Equity VS FCFPHAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 2.23 indicates that PHAT has no problem at all paying its short term obligations.
The Current ratio of PHAT (2.23) is comparable to the rest of the industry.
PHAT has a Quick Ratio of 2.19. This indicates that PHAT is financially healthy and has no problem in meeting its short term obligations.
PHAT's Quick ratio of 2.19 is in line compared to the rest of the industry. PHAT outperforms 44.79% of its industry peers.
Industry RankSector Rank
Current Ratio 2.23
Quick Ratio 2.19
PHAT Yearly Current Assets VS Current LiabilitesPHAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

PHAT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.86%, which is quite impressive.
PHAT shows a strong growth in Revenue. In the last year, the Revenue has grown by 460.30%.
EPS 1Y (TTM)32.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.94%
Revenue 1Y (TTM)460.3%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%202.74%

3.2 Future

The Earnings Per Share is expected to grow by 24.29% on average over the next years. This is a very strong growth
Based on estimates for the next years, PHAT will show a very strong growth in Revenue. The Revenue will grow by 76.12% on average per year.
EPS Next Y38.5%
EPS Next 2Y34.98%
EPS Next 3Y30.53%
EPS Next 5Y24.29%
Revenue Next Year241.49%
Revenue Next 2Y152.8%
Revenue Next 3Y115.7%
Revenue Next 5Y76.12%

3.3 Evolution

PHAT Yearly Revenue VS EstimatesPHAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
PHAT Yearly EPS VS EstimatesPHAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PHAT. In the last year negative earnings were reported.
Also next year PHAT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PHAT Price Earnings VS Forward Price EarningsPHAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PHAT Per share dataPHAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as PHAT's earnings are expected to grow with 30.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.98%
EPS Next 3Y30.53%

More info and screens

0

5. Dividend

5.1 Amount

PHAT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHATHOM PHARMACEUTICALS INC

NASDAQ:PHAT (11/25/2025, 8:06:46 PM)

After market: 14.64 -0.29 (-1.94%)

14.93

+0.11 (+0.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)03-04 2026-03-04/amc
Inst Owners65.5%
Inst Owner Change5.13%
Ins Owners1.99%
Ins Owner Change1.85%
Market Cap1.06B
Revenue(TTM)147.19M
Net Income(TTM)-274.55M
Analysts84
Price Target22.95 (53.72%)
Short Float %24.6%
Short Ratio11.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.63%
Min EPS beat(2)1.02%
Max EPS beat(2)26.25%
EPS beat(4)3
Avg EPS beat(4)8.58%
Min EPS beat(4)-12%
Max EPS beat(4)26.25%
EPS beat(8)4
Avg EPS beat(8)0.51%
EPS beat(12)8
Avg EPS beat(12)5.88%
EPS beat(16)10
Avg EPS beat(16)2.93%
Revenue beat(2)2
Avg Revenue beat(2)5.31%
Min Revenue beat(2)3.28%
Max Revenue beat(2)7.35%
Revenue beat(4)3
Avg Revenue beat(4)5.94%
Min Revenue beat(4)-3.64%
Max Revenue beat(4)16.75%
Revenue beat(8)6
Avg Revenue beat(8)16.03%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.26%
PT rev (3m)5.26%
EPS NQ rev (1m)-0.93%
EPS NQ rev (3m)-0.93%
EPS NY rev (1m)1.44%
EPS NY rev (3m)5.4%
Revenue NQ rev (1m)0.85%
Revenue NQ rev (3m)3.28%
Revenue NY rev (1m)1.51%
Revenue NY rev (3m)3.53%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.2
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.82
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-3.18
FCFYN/A
OCF(TTM)-3.17
OCFYN/A
SpS2.07
BVpS-5.96
TBVpS-5.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -114.26%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.25%
FCFM N/A
ROA(3y)-85.69%
ROA(5y)-75.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.06%
Cap/Sales 0.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.23
Quick Ratio 2.19
Altman-Z -9.31
F-Score3
WACC8.13%
ROIC/WACCN/A
Cap/Depr(3y)156.3%
Cap/Depr(5y)171.47%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.94%
EPS Next Y38.5%
EPS Next 2Y34.98%
EPS Next 3Y30.53%
EPS Next 5Y24.29%
Revenue 1Y (TTM)460.3%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%202.74%
Revenue Next Year241.49%
Revenue Next 2Y152.8%
Revenue Next 3Y115.7%
Revenue Next 5Y76.12%
EBIT growth 1Y25.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.81%
EBIT Next 3Y37.46%
EBIT Next 5Y31.42%
FCF growth 1Y-65.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-67.48%
OCF growth 3YN/A
OCF growth 5YN/A

PHATHOM PHARMACEUTICALS INC / PHAT FAQ

What is the ChartMill fundamental rating of PHATHOM PHARMACEUTICALS INC (PHAT) stock?

ChartMill assigns a fundamental rating of 2 / 10 to PHAT.


Can you provide the valuation status for PHATHOM PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 1 / 10 to PHATHOM PHARMACEUTICALS INC (PHAT). This can be considered as Overvalued.


Can you provide the profitability details for PHATHOM PHARMACEUTICALS INC?

PHATHOM PHARMACEUTICALS INC (PHAT) has a profitability rating of 1 / 10.


What is the financial health of PHATHOM PHARMACEUTICALS INC (PHAT) stock?

The financial health rating of PHATHOM PHARMACEUTICALS INC (PHAT) is 2 / 10.


What is the expected EPS growth for PHATHOM PHARMACEUTICALS INC (PHAT) stock?

The Earnings per Share (EPS) of PHATHOM PHARMACEUTICALS INC (PHAT) is expected to grow by 38.5% in the next year.